Shots:

• The P-III EDITION JUNIOR study involves assessing Toujeo vs Gla-100 (insulin glargine 100 Units/mL) in 463 children and adolescents aged 6-17yrs. with T1D for at least 1yr. and with HbA1c b/w 7.5% and 11.0% at screening
• The P-III EDITION JUNIOR study resulted in meeting its 1EPs i.e- reduction in average blood sugar over 6 months with both treatments and similar risk of hypoglycemia; the lower number of patients experienced severe hypoglycemia & hyperglycemia with ketosis
• Toujeo is long-acting insulin for adults with diabetes- regulating blood sugar level and has received EMA’s CHMP positive opinion for expanded indication in children and adolescents aged 6-17yrs. with diabetes with the anticipated EC’s decision in the coming months

Click here to­ read full press release/ article | Ref: Sanofi | Image: The Diabetes Times